{"hands_on_practices": [{"introduction": "A toxicology screen's performance is often described by its sensitivity and specificity, but these metrics don't directly answer the clinician's crucial question: 'Given this test result, what is the probability my patient actually used the drug?' This practice explores Positive and Negative Predictive Values (PPV and NPV), which bridge this gap by incorporating the prevalence of drug use in the tested population. By working through this problem [@problem_id:5239052], you will see how a test with excellent analytical characteristics can perform differently in various clinical settings and understand the vital role of confirmatory testing.", "problem": "A clinical laboratory uses a urine opiate immunoassay (IA) as a screening test in an emergency department population. In method validation, the test performance characteristics were measured as sensitivity $0.95$ and specificity $0.98$. Epidemiologic surveillance indicates the pretest prevalence of true opiate exposure in this tested population is $0.01$. Starting from first principles of conditional probability and Bayes’ theorem, and using the standard definitions of sensitivity, specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV), derive the analytic expressions for PPV and NPV in terms of sensitivity, specificity, and prevalence. Then compute the numerical values of PPV and NPV for this test-population combination. Express both PPV and NPV as decimal fractions and round your answers to four significant figures. Finally, based on your computed values, discuss the clinical implications for the use of the immunoassay, including the role of confirmatory testing by Gas Chromatography–Mass Spectrometry (GC-MS).", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. All necessary data (sensitivity, specificity, prevalence) are provided, and the values are realistic for the described clinical scenario. The problem adheres to standard principles of diagnostic test evaluation in biostatistics and clinical laboratory science. Therefore, the problem is valid and a solution will be provided.\n\nLet $D$ be the event that a patient has true opiate exposure (the \"disease\" is present), and let $\\neg D$ be the event that the patient has no opiate exposure. Let $T$ be the event of a positive test result from the immunoassay, and let $\\neg T$ be the event of a negative test result.\n\nThe givens can be formally expressed in terms of conditional probabilities:\n-   Prevalence, $P(D) = 0.01$. From this, the probability of not having the disease is $P(\\neg D) = 1 - P(D) = 1 - 0.01 = 0.99$.\n-   Sensitivity (Sens), the probability of a positive test given disease, is $P(T|D) = 0.95$.\n-   Specificity (Spec), the probability of a negative test given no disease, is $P(\\neg T|\\neg D) = 0.98$.\n\nFrom these definitions, we can also define the false negative and false positive rates:\n-   False Negative Rate (FNR) is $P(\\neg T|D) = 1 - P(T|D) = 1 - \\text{Sens} = 1 - 0.95 = 0.05$.\n-   False Positive Rate (FPR) is $P(T|\\neg D) = 1 - P(\\neg T|\\neg D) = 1 - \\text{Spec} = 1 - 0.98 = 0.02$.\n\n**Part 1: Derivation of Analytic Expressions**\n\nThe Positive Predictive Value (PPV) is the probability that a patient with a positive test result truly has the disease, i.e., $P(D|T)$.\nUsing Bayes' theorem:\n$$\nPPV = P(D|T) = \\frac{P(T|D) P(D)}{P(T)}\n$$\nThe denominator, $P(T)$, is the total probability of a positive test. It can be found using the law of total probability, summing over the two mutually exclusive states of disease (present or absent):\n$$\nP(T) = P(T|D)P(D) + P(T|\\neg D)P(\\neg D)\n$$\nSubstituting the terms for sensitivity, specificity, and prevalence (letting $P=P(D)$):\n$$\nP(T) = (\\text{Sens}) \\cdot P + (1 - \\text{Spec}) \\cdot (1 - P)\n$$\nSubstituting this back into the expression for PPV gives the final analytic form:\n$$\nPPV = \\frac{(\\text{Sens}) \\cdot P}{(\\text{Sens}) \\cdot P + (1 - \\text{Spec}) \\cdot (1 - P)}\n$$\n\nThe Negative Predictive Value (NPV) is the probability that a patient with a negative test result is truly free of the disease, i.e., $P(\\neg D|\\neg T)$.\nUsing Bayes' theorem:\n$$\nNPV = P(\\neg D|\\neg T) = \\frac{P(\\neg T|\\neg D) P(\\neg D)}{P(\\neg T)}\n$$\nThe denominator, $P(\\neg T)$, is the total probability of a negative test, found using the law of total probability:\n$$\nP(\\neg T) = P(\\neg T|D)P(D) + P(\\neg T|\\neg D)P(\\neg D)\n$$\nSubstituting the terms for sensitivity, specificity, and prevalence:\n$$\nP(\\neg T) = (1 - \\text{Sens}) \\cdot P + (\\text{Spec}) \\cdot (1 - P)\n$$\nSubstituting this back into the expression for NPV gives the final analytic form:\n$$\nNPV = \\frac{(\\text{Spec}) \\cdot (1 - P)}{(1 - \\text{Sens}) \\cdot P + (\\text{Spec}) \\cdot (1 - P)}\n$$\n\n**Part 2: Computation of Numerical Values**\n\nUsing the derived expressions and the given numerical values:\n$\\text{Sens} = 0.95$, $\\text{Spec} = 0.98$, and $P = 0.01$.\n\nFor PPV:\n$$\nPPV = \\frac{0.95 \\times 0.01}{0.95 \\times 0.01 + (1 - 0.98) \\times (1 - 0.01)} = \\frac{0.0095}{0.0095 + 0.02 \\times 0.99} = \\frac{0.0095}{0.0095 + 0.0198} = \\frac{0.0095}{0.0293}\n$$\n$$\nPPV \\approx 0.32423208...\n$$\nRounded to four significant figures, $PPV = 0.3242$.\n\nFor NPV:\n$$\nNPV = \\frac{0.98 \\times (1 - 0.01)}{(1 - 0.95) \\times 0.01 + 0.98 \\times (1 - 0.01)} = \\frac{0.98 \\times 0.99}{0.05 \\times 0.01 + 0.98 \\times 0.99} = \\frac{0.9702}{0.0005 + 0.9702} = \\frac{0.9702}{0.9707}\n$$\n$$\nNPV \\approx 0.9994848...\n$$\nRounded to four significant figures, $NPV = 0.9995$.\n\n**Part 3: Discussion of Clinical Implications**\n\nThe computed Positive Predictive Value (PPV) is $0.3242$, meaning that only about $32.4\\%$ of positive screening tests in this population will reflect true opiate exposure. Conversely, about $67.6\\%$ of positive results are false positives. This low PPV is a direct consequence of the low prevalence ($1\\%$) of the condition in the tested population, even with a test that has high sensitivity and specificity. Relying on a positive immunoassay result alone to diagnose opiate use would lead to a high rate of misdiagnosis.\n\nThe computed Negative Predictive Value (NPV) is $0.9995$, which is extremely high. This means that a negative test result is very reliable; there is a $99.95\\%$ probability that a person with a negative result has not been exposed to opiates.\n\nThe clinical implication is that this immunoassay serves as an excellent **screening test** to **rule out** opiate exposure due to its high NPV. A negative result provides strong evidence to pursue other diagnoses. However, due to its low PPV, it is a poor **confirmatory test**. Any positive result from this immunoassay must be considered presumptive and requires confirmation by a method with higher specificity, such as Gas Chromatography–Mass Spectrometry (GC-MS). GC-MS is considered a gold standard because it structurally identifies the molecule, nearly eliminating false positives ($Specificity \\approx 1.00$). The standard clinical workflow is a two-tiered approach: screen with the sensitive but less specific immunoassay, and then confirm all positive screens with the highly specific GC-MS method. This strategy maximizes the identification of potential positives while ensuring that final diagnostic conclusions are based on highly reliable evidence, thereby preventing the serious medical and social consequences of a false-positive result.", "answer": "$$\\boxed{\\begin{pmatrix} 0.3242 & 0.9995 \\end{pmatrix}}$$", "id": "5239052"}, {"introduction": "The concentration of a drug in a urine sample is not just a function of dosage and metabolism, but also of the patient's hydration status, which can vary dramatically. This practice addresses this common pre-analytical variable by exploring creatinine normalization, the standard method for adjusting urine drug concentrations. By deriving the relationship between dilution and concentration [@problem_id:5238992], you will gain a fundamental understanding of how this correction makes results more reliable and less susceptible to manipulation through fluid intake.", "problem": "A clinical toxicology laboratory receives a urine specimen for drugs-of-abuse confirmation. The laboratory aims to interpret the concentration of an analyte in the presence of variable hydration by normalizing to creatinine. Assume the following scientifically grounded principles:\n- Concentration is defined as amount per unit volume, so if the amount of a solute in a compartment remains constant while volume changes, the concentration scales inversely with volume.\n- In a short time frame (single void), water ingestion leading to a larger bladder volume does not alter the number of moles of the analyte or creatinine already present in that compartment just prior to voiding, so their amounts are conserved during a pure dilution event.\n\nYou are given a patient’s pre-dilution bladder contents characterized by an analyte concentration $C_{a0}$ and a creatinine concentration $C_{cr0}$. The patient then ingests water, and by the time of voiding the bladder volume has increased by a factor $d$ without additional net production or loss of analyte or creatinine in the bladder compartment. The laboratory reports the post-dilution concentrations $C_{a1}$ and $C_{cr1}$. To adjust for hydration, the laboratory wishes to report a creatinine-normalized analyte concentration referenced to a standard creatinine concentration $C_{cr,\\mathrm{ref}}$ by scaling the observed analyte according to the ratio $C_{cr,\\mathrm{ref}}/C_{cr1}$.\n\nTasks:\n1. Starting from the definition of concentration and conservation of amount for both analyte and creatinine across the dilution, derive the general expressions relating $C_{a1}$ and $C_{cr1}$ to $C_{a0}$, $C_{cr0}$, and $d$. Then derive the expression for the creatinine-normalized analyte concentration $C_{a,\\mathrm{norm}}$ referenced to $C_{cr,\\mathrm{ref}}$ in terms of $C_{a1}$, $C_{cr1}$, and $C_{cr,\\mathrm{ref}}$.\n2. Using your derived relationships, evaluate $C_{a,\\mathrm{norm}}$ for the following measured values: $C_{a0} = 850 \\,\\mathrm{ng/mL}$, $C_{cr0} = 1.5 \\,\\mathrm{g/L}$, a dilution factor $d = 3.2$, and a reference creatinine $C_{cr,\\mathrm{ref}} = 1.0 \\,\\mathrm{g/L}$. Express the final creatinine-normalized analyte concentration in $\\mathrm{ng/mL}$.\n\nRound your final numerical answer to $4$ significant figures.", "solution": "The problem has been validated and is determined to be sound, well-posed, objective, and scientifically grounded. The principles of concentration, dilution, and creatinine normalization are fundamental to clinical toxicology. The problem provides all necessary information for a complete solution.\n\n### Task 1: Derivation of Analytical Expressions\n\nWe begin by formalizing the relationships based on the provided principles. Let $n_a$ and $n_{cr}$ be the amounts (e.g., in moles or mass) of the analyte and creatinine, respectively, present in the bladder. Let $V_0$ be the initial bladder volume.\n\nThe initial (pre-dilution) concentrations are defined as:\n$$C_{a0} = \\frac{n_a}{V_0}$$\n$$C_{cr0} = \\frac{n_{cr}}{V_0}$$\n\nFollowing the ingestion of water, the bladder volume increases by a factor of $d$. The new volume, $V_1$, is:\n$$V_1 = d \\cdot V_0$$\n\nAccording to the principle of conservation of amount during this pure dilution event, $n_a$ and $n_{cr}$ remain constant. The new, post-dilution concentrations, $C_{a1}$ and $C_{cr1}$, are:\n$$C_{a1} = \\frac{n_a}{V_1}$$\n$$C_{cr1} = \\frac{n_{cr}}{V_1}$$\n\nTo relate the post-dilution concentrations to the pre-dilution concentrations, we substitute the expressions for $n_a$, $n_{cr}$, and $V_1$.\nFor the analyte:\n$$C_{a1} = \\frac{C_{a0} V_0}{d V_0} = \\frac{C_{a0}}{d}$$\n\nFor creatinine:\n$$C_{cr1} = \\frac{C_{cr0} V_0}{d V_0} = \\frac{C_{cr0}}{d}$$\n\nThese are the general expressions relating the post-dilution concentrations to the pre-dilution concentrations and the dilution factor $d$.\n\nNext, we derive the expression for the creatinine-normalized analyte concentration, $C_{a,\\mathrm{norm}}$. The problem states that this is calculated by scaling the observed analyte concentration, $C_{a1}$, by the ratio of a reference creatinine concentration, $C_{cr,\\mathrm{ref}}$, to the observed creatinine concentration, $C_{cr1}$. The formula is thus given as:\n$$C_{a,\\mathrm{norm}} = C_{a1} \\frac{C_{cr,\\mathrm{ref}}}{C_{cr1}}$$\nThis completes the derivation portion of the task.\n\n### Task 2: Numerical Evaluation\n\nWe are asked to evaluate $C_{a,\\mathrm{norm}}$ using the derived relationships and the given values. First, we can substitute the expressions for $C_{a1}$ and $C_{cr1}$ into the normalization formula:\n$$C_{a,\\mathrm{norm}} = \\left(\\frac{C_{a0}}{d}\\right) \\frac{C_{cr,\\mathrm{ref}}}{\\left(\\frac{C_{cr0}}{d}\\right)}$$\n\nThe dilution factor $d$ cancels out from the numerator and denominator:\n$$C_{a,\\mathrm{norm}} = \\frac{C_{a0}}{d} \\cdot \\frac{d \\cdot C_{cr,\\mathrm{ref}}}{C_{cr0}} = C_{a0} \\frac{C_{cr,\\mathrm{ref}}}{C_{cr0}}$$\n\nThis result demonstrates a key feature of creatinine normalization: it mathematically corrects for the effects of dilution, making the final reported value independent of the dilution factor $d$.\n\nNow, we substitute the provided numerical values into this simplified expression:\n- $C_{a0} = 850 \\,\\mathrm{ng/mL}$\n- $C_{cr0} = 1.5 \\,\\mathrm{g/L}$\n- $C_{cr,\\mathrm{ref}} = 1.0 \\,\\mathrm{g/L}$\n\nThe units for the creatinine concentrations ($C_{cr0}$ and $C_{cr,\\mathrm{ref}}$) are consistent ($\\mathrm{g/L}$), so their ratio will be a dimensionless quantity. The calculation is as follows:\n$$C_{a,\\mathrm{norm}} = (850 \\,\\mathrm{ng/mL}) \\cdot \\frac{1.0 \\,\\mathrm{g/L}}{1.5 \\,\\mathrm{g/L}}$$\n$$C_{a,\\mathrm{norm}} = 850 \\cdot \\frac{1.0}{1.5} \\,\\mathrm{ng/mL}$$\n$$C_{a,\\mathrm{norm}} = 850 \\cdot \\frac{2}{3} \\,\\mathrm{ng/mL}$$\n$$C_{a,\\mathrm{norm}} = \\frac{1700}{3} \\,\\mathrm{ng/mL}$$\n$$C_{a,\\mathrm{norm}} \\approx 566.666... \\,\\mathrm{ng/mL}$$\n\nThe problem requires the final numerical answer to be rounded to $4$ significant figures.\n$$C_{a,\\mathrm{norm}} = 566.7 \\,\\mathrm{ng/mL}$$\nThis is the final creatinine-normalized analyte concentration.", "answer": "$$\\boxed{566.7}$$", "id": "5238992"}, {"introduction": "The cutoff value that separates a 'positive' from a 'negative' result on a drug screen is a critical decision point with significant consequences. Where should this line be drawn? This practice moves beyond simply using a given cutoff to explore how cutoffs are rationally determined by balancing the competing needs of sensitivity and specificity. Using concepts from Receiver Operating Characteristic (ROC) analysis [@problem_id:5239002], you will learn how to derive a cost-minimizing threshold that explicitly accounts for the prevalence of a drug and the asymmetric costs of false-positive and false-negative results.", "problem": "A clinical laboratory uses a urine immunoassay for morphine in workplace testing. The instrument reports a continuous concentration estimate $x$ in nanograms per milliliter (ng/mL). A sample is reported as \"screen-positive\" if $x \\ge t$, where $t$ is the decision threshold (cutoff). The laboratory director wants to select $t$ to minimize expected decision cost while considering asymmetric consequences of false positives and false negatives.\n\nAssume the following scientifically plausible model and context:\n- In individuals truly without recent morphine exposure (the \"negative\" class), the reported concentration $x$ has a distribution $x \\sim \\mathcal{N}(\\mu_0, \\sigma^2)$ with $\\mu_0 = 30$ ng/mL and $\\sigma = 25$ ng/mL, reflecting baseline signal and biological variability.\n- In individuals truly with recent morphine exposure (the \"positive\" class), the reported concentration $x \\sim \\mathcal{N}(\\mu_1, \\sigma^2)$ with $\\mu_1 = 200$ ng/mL and the same $\\sigma = 25$ ng/mL, reflecting higher signal with similar analytical imprecision.\n- The prevalence of true recent morphine exposure among those tested is $\\pi = 0.10$.\n- The unit cost assigned to a false positive is $C_{\\mathrm{FP}} = 1$ (arbitrary units), and to a false negative is $C_{\\mathrm{FN}} = 8$ (arbitrary units), capturing the asymmetry in consequences.\n\nStarting from the core definitions of sensitivity and specificity, the probabilistic structure of the two-class model, and the decision-theoretic principle that the optimal threshold minimizes expected cost, use Receiver Operating Characteristic (ROC) analysis to derive an analytic expression for the cost-minimizing threshold $t$ in terms of $\\mu_0$, $\\mu_1$, $\\sigma$, $\\pi$, $C_{\\mathrm{FP}}$, and $C_{\\mathrm{FN}}$. Then, evaluate $t$ numerically for the parameter values given above.\n\nRound your final numeric answer to four significant figures. Express the final threshold concentration in ng/mL.", "solution": "The problem is valid as it is scientifically grounded, well-posed, objective, and contains all necessary information for a unique and meaningful solution. It represents a standard application of statistical decision theory to laboratory diagnostics.\n\nThe objective is to find the decision threshold $t$ that minimizes the total expected cost of misclassification. The expected cost, $E[C(t)]$, is the sum of the costs of false positives and false negatives, weighted by their respective probabilities of occurrence.\n\nLet $D_0$ denote the event that an individual is truly negative (no morphine exposure) and $D_1$ denote the event that an individual is truly positive (with morphine exposure). The problem provides the prevalences of these two classes:\n$P(D_1) = \\pi = 0.10$\n$P(D_0) = 1 - \\pi = 0.90$\n\nThe test measurement, $x$, is a continuous variable. A sample is classified as positive if its measurement $x$ is greater than or equal to the threshold $t$, and negative otherwise.\nThe distributions of $x$ for the two classes are given as normal (Gaussian) distributions with a shared variance:\nFor the negative class $D_0$: $x \\sim \\mathcal{N}(\\mu_0, \\sigma^2)$, with PDF $f_0(x)$.\nFor the positive class $D_1$: $x \\sim \\mathcal{N}(\\mu_1, \\sigma^2)$, with PDF $f_1(x)$.\n\nA false positive (FP) occurs when a truly negative individual ($D_0$) is classified as positive ($x \\ge t$). The probability of this event is the false positive rate, $\\text{FPR}(t)$.\nA false negative (FN) occurs when a truly positive individual ($D_1$) is classified as negative ($x < t$). The probability of this event is the false negative rate, $\\text{FNR}(t)$.\n\nThe probabilities of these errors are given by:\n$\\text{FPR}(t) = P(x \\ge t | D_0) = \\int_{t}^{\\infty} f_0(x) dx$\n$\\text{FNR}(t) = P(x < t | D_1) = \\int_{-\\infty}^{t} f_1(x) dx$\n\nThe costs associated with these errors are $C_{\\mathrm{FP}}$ and $C_{\\mathrm{FN}}$. The total expected cost function $E[C(t)]$ is the sum of the costs of each type of error, each multiplied by the prior probability of that class:\n$E[C(t)] = P(\\text{FP}) \\cdot C_{\\mathrm{FP}} + P(\\text{FN}) \\cdot C_{\\mathrm{FN}}$\n$P(\\text{FP}) = P(x \\ge t \\text{ and } D_0) = P(x \\ge t | D_0) P(D_0) = \\text{FPR}(t) \\cdot (1-\\pi)$\n$P(\\text{FN}) = P(x < t \\text{ and } D_1) = P(x < t | D_1) P(D_1) = \\text{FNR}(t) \\cdot \\pi$\n\nSubstituting these into the cost function:\n$E[C(t)] = (1-\\pi) C_{\\mathrm{FP}} \\int_{t}^{\\infty} f_0(x) dx + \\pi C_{\\mathrm{FN}} \\int_{-\\infty}^{t} f_1(x) dx$\n\nTo find the threshold $t$ that minimizes this cost, we differentiate $E[C(t)]$ with respect to $t$ and set the derivative to zero. Using the Fundamental Theorem of Calculus (specifically, Leibniz's rule for differentiation of integrals), we have:\n$\\frac{d}{dt} \\int_{t}^{\\infty} f_0(x) dx = -f_0(t)$\n$\\frac{d}{dt} \\int_{-\\infty}^{t} f_1(x) dx = f_1(t)$\n\nApplying this to the cost function derivative:\n$\\frac{dE[C(t)]}{dt} = (1-\\pi) C_{\\mathrm{FP}} (-f_0(t)) + \\pi C_{\\mathrm{FN}} (f_1(t))$\n\nSetting the derivative to zero to find the optimal threshold, which we denote as $t^*$:\n$\\pi C_{\\mathrm{FN}} f_1(t^*) - (1-\\pi) C_{\\mathrm{FP}} f_0(t^*) = 0$\n$\\pi C_{\\mathrm{FN}} f_1(t^*) = (1-\\pi) C_{\\mathrm{FP}} f_0(t^*)$\n\nThis can be rearranged to show that at the optimal threshold, the likelihood ratio of the two classes equals the ratio of costs and prevalences:\n$$ \\frac{f_1(t^*)}{f_0(t^*)} = \\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}} $$\nThis is a central result in statistical decision theory and ROC analysis, defining the optimal operating point.\n\nNow, we substitute the probability density functions for the two normal distributions:\n$f_0(x) = \\frac{1}{\\sqrt{2\\pi}\\sigma} \\exp\\left(-\\frac{(x - \\mu_0)^2}{2\\sigma^2}\\right)$\n$f_1(x) = \\frac{1}{\\sqrt{2\\pi}\\sigma} \\exp\\left(-\\frac{(x - \\mu_1)^2}{2\\sigma^2}\\right)$\n\nThe ratio of the PDFs is:\n$$ \\frac{\\frac{1}{\\sqrt{2\\pi}\\sigma} \\exp\\left(-\\frac{(t^* - \\mu_1)^2}{2\\sigma^2}\\right)}{\\frac{1}{\\sqrt{2\\pi}\\sigma} \\exp\\left(-\\frac{(t^* - \\mu_0)^2}{2\\sigma^2}\\right)} = \\exp\\left(-\\frac{(t^* - \\mu_1)^2}{2\\sigma^2} + \\frac{(t^* - \\mu_0)^2}{2\\sigma^2}\\right) = \\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}} $$\nTaking the natural logarithm of both sides:\n$$ \\frac{(t^* - \\mu_0)^2 - (t^* - \\mu_1)^2}{2\\sigma^2} = \\ln\\left(\\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}}\\right) $$\nExpanding the terms in the numerator:\n$(t^{*2} - 2t^*\\mu_0 + \\mu_0^2) - (t^{*2} - 2t^*\\mu_1 + \\mu_1^2) = 2t^*(\\mu_1 - \\mu_0) + \\mu_0^2 - \\mu_1^2$\nThe term $\\mu_0^2 - \\mu_1^2$ can be factored as $-(\\mu_1 - \\mu_0)(\\mu_1 + \\mu_0)$.\nSo, the numerator becomes $2t^*(\\mu_1 - \\mu_0) - (\\mu_1 - \\mu_0)(\\mu_1 + \\mu_0)$.\n\nSubstituting this back into the equation:\n$$ \\frac{2t^*(\\mu_1 - \\mu_0) - (\\mu_1 - \\mu_0)(\\mu_1 + \\mu_0)}{2\\sigma^2} = \\ln\\left(\\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}}\\right) $$\nNow, we solve for $t^*$. Multiply by $2\\sigma^2$:\n$$ 2t^*(\\mu_1 - \\mu_0) - (\\mu_1 - \\mu_0)(\\mu_1 + \\mu_0) = 2\\sigma^2 \\ln\\left(\\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}}\\right) $$\nIsolate the term with $t^*$:\n$$ 2t^*(\\mu_1 - \\mu_0) = (\\mu_1 + \\mu_0)(\\mu_1 - \\mu_0) + 2\\sigma^2 \\ln\\left(\\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}}\\right) $$\nDivide by $2(\\mu_1 - \\mu_0)$, which is valid since $\\mu_1 \\neq \\mu_0$:\n$$ t^* = \\frac{(\\mu_1 + \\mu_0)(\\mu_1 - \\mu_0)}{2(\\mu_1 - \\mu_0)} + \\frac{2\\sigma^2}{2(\\mu_1 - \\mu_0)} \\ln\\left(\\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}}\\right) $$\nThis simplifies to the final analytical expression for the cost-minimizing threshold:\n$$ t^* = \\frac{\\mu_0 + \\mu_1}{2} + \\frac{\\sigma^2}{\\mu_1 - \\mu_0} \\ln\\left(\\frac{(1-\\pi)C_{\\mathrm{FP}}}{\\pi C_{\\mathrm{FN}}}\\right) $$\nNow, we substitute the numerical values provided in the problem:\n$\\mu_0 = 30$\n$\\mu_1 = 200$\n$\\sigma = 25$\n$\\pi = 0.10$\n$C_{\\mathrm{FP}} = 1$\n$C_{\\mathrm{FN}} = 8$\n\n$t^* = \\frac{30 + 200}{2} + \\frac{25^2}{200 - 30} \\ln\\left(\\frac{(1-0.10) \\times 1}{0.10 \\times 8}\\right)$\n$t^* = \\frac{230}{2} + \\frac{625}{170} \\ln\\left(\\frac{0.9}{0.8}\\right)$\n$t^* = 115 + \\frac{625}{170} \\ln(1.125)$\n\nCalculating the values:\n$\\ln(1.125) \\approx 0.1177833$\n$\\frac{625}{170} \\approx 3.6764706$\n\n$t^* \\approx 115 + (3.6764706) \\times (0.1177833)$\n$t^* \\approx 115 + 0.4330174$\n$t^* \\approx 115.4330174$\n\nThe problem requires the final answer to be rounded to four significant figures.\n$t^* \\approx 115.4$\n\nThe optimal threshold concentration is $115.4$ ng/mL.", "answer": "$$ \\boxed{115.4} $$", "id": "5239002"}]}